NextCure Provides Business Update and Reports Full Year 2024 Financial Results

Core Insights - NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment, reporting a business update and full-year financial results for 2024 [1][6]. Business Highlights and Near-Term Milestones - The company has reprioritized resources to advance its antibody-drug conjugate (ADC) program, specifically LNCB74, and completed cohort 1 of the Phase 1 study for multiple cancers [2][3]. - Plans to initiate backfill cohorts for LNCB74 in the second half of 2025 [2][8]. - Preclinical data for LNCB74 was presented at the Society of Immunotherapy of Cancer annual meeting in November 2024, showcasing its potential for multiple solid tumor indications [8]. Financial Results for Full Year Ended December 31, 2024 - Cash, cash equivalents, and marketable securities decreased to approximately $68.6 million from$108.3 million in 2023, primarily due to operational funding [7][13]. - Research and development expenses were $41.5 million, down from$47.9 million in 2023, while general and administrative expenses decreased to $15.7 million from$19.7 million [8][11]. - The net loss for 2024 was $55.7 million, an improvement from a net loss of$62.7 million in 2023, with a net loss per share of $1.99 compared to$2.25 in the previous year [11][12].